Trial Profile

Phase 2 study of daratumumab monotherapy in previously untreated patients with stage 3B light chain (AL) amyloidosis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Bortezomib; Dexamethasone
Indications Amyloid light-chain amyloidosis
Focus Therapeutic Use
Acronyms EMN22

Most Recent Events

16 Apr 2025 Status changed from active, no longer recruiting to completed.
12 Dec 2023 Results (n=9) assessing efficacy and safety of daratumumab monotherapy in newly diagnosed patients with amyloidosis, presented at the 65th American Society of Hematology Annual Meeting and Exposition
13 Mar 2023 Planned End Date changed from 30 Nov 2023 to 1 Jan 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com